Eligibility, sequence listings, disclosure standards and claim strategy for peptide therapeutics
Introduction
Peptide therapeutics have moved from niche to mainstream. Drugs such as GLP-1 receptor agonists, along with new classes of cyclic, stapled and lipidated peptides, have made peptides one of the most commercially important categories of pharmaceutical innovation. Protecting them requires more than a standard small-molecule filing, because peptide inventions are defined by sequences and sequences bring specific formal rules, disclosure standards and strategic choices.
This article reviews the main requirements for filing patent applications that involve peptide sequences, with emphasis on United States practice and notes on the European Patent Office (EPO) and the Patent Cooperation Treaty (PCT).
1. What Makes Peptide Patents Different
Peptides sit between small molecules and large biologics. They are chains of amino acids, usually fewer than about 40 residues and can be natural, synthetic or modified. That position has three consequences for patenting:
- Sequence-defined claims. Claims often recite amino acid sequences, which must be described in a standardized electronic format.
- Eligibility questions. Natural peptides raise subject-matter eligibility issues that do not usually arise for synthetic small molecules.
- Variant breadth. Applicants want to claim families of related sequences, but broad claims face written-description and enablement challenges.
Regulatory note: The FDA treats a protein as a chain of more than 40 amino acids, so peptides of 40 or fewer amino acids are generally regulated as drugs under the Federal Food, Drug and Cosmetic Act rather than as biological products under the BPCIA. This affects which exclusivity and patent-listing frameworks apply (for example, Orange Book listing and Hatch-Waxman patent term extension) and it should inform filing strategy early.
2. Patent Eligibility (35 U.S.C. § 101)
In the United States, naturally occurring products are judicial exceptions to eligibility. Following the Supreme Court’s decision in Association for Molecular Pathology v. Myriad Genetics (2013) and subsequent USPTO guidance, a claim to a peptide that is merely an isolated naturally occurring sequence is at risk of rejection. Eligibility is more secure where the claimed peptide has markedly different characteristics from any naturally occurring counterpart.
Ways to strengthen eligibility include:
- Structural modifications not found in nature, such as D-amino acids, non-natural amino acids, N-terminal or C-terminal capping, cyclization, stapling, lipidation, PEGylation or conjugation to other moieties.
- Non-natural sequences, including substitutions, truncations or fusions that create new properties.
- Method of treatment claims, which apply a peptide to a particular patient population or condition and are generally eligible if they include a practical application.
- Formulation and delivery claims, such as particular excipients, dosage forms, or devices.
- Manufacturing process claims, including synthesis, purification or stabilization methods.
In Europe, the EPC allows patents on isolated natural substances, including peptides, if they are novel and industrially applicable, but a use must be disclosed. The more significant European hurdles tend to be inventive step and sufficiency.
3. Sequence Listing Requirements
Any application disclosing or claiming specifically defined amino acid sequences generally must include a sequence listing. Since July 1, 2022, the USPTO, EPO and many other offices require sequence listings in WIPO Standard ST.26, which is an XML format. It replaced the earlier ST.25 text format and, in the United States, the former rules at 37 C.F.R. §§ 1.821 to 1.825 as they applied to new filings.
| Topic | Requirement (general summary; verify current rules) |
| Threshold | Amino acid sequences of four or more specifically defined amino acids and nucleotide sequences of ten or more specifically defined nucleotides, must be listed. |
| Format | ST.26 XML file. It is generated and validated using WIPO Sequence software, then submitted electronically (in the U.S. through Patent Center). |
| Identifiers | Each sequence is assigned a sequence identifier (SEQ ID NO:) in numerical order. The same numbers must be used in the description and claims. |
| Modified residues | Unusual, modified or non-standard residues (for example D-amino acids, non-natural amino acids and chemical modifications) are generally represented using the symbol “X” together with feature annotations that describe the modification. |
| Branched and cyclic structures | Structures that cannot be fully expressed as a linear sequence may need to be described in the specification and drawings, with the sequence listing capturing what the standard allows. |
| Page count and fees | The sequence listing is submitted as a separate XML file and is generally not counted toward application page-count fees. |
| Consistency | The listing must not introduce new matter and must match sequences disclosed in the specification, drawings and claims. |
| Errors | Non-compliant listings lead to notices requiring correction, which can add delay and cost and, in some cases, jeopardize a filing date or priority claim in other offices if not handled correctly. |
Reference to sequences in the text should use the standard one-letter or three-letter amino acid codes and the SEQ ID NO: designation. Where a sequence is not required in the listing (for example, fewer than four defined residues), it can be described in the text, but consider whether to include it in the listing anyway for consistency.
4. Disclosure Requirements (35 U.S.C. § 112)
Written description
The specification must show that the inventor possessed the claimed invention at filing. For peptide genus claims (for example, any peptide with at least 90 percent identity to a reference sequence that binds a given target), the applicant should describe enough representative species, or common structural features, to demonstrate possession of the full genus. A single working sequence is rarely enough to support a wide family.
Enablement
The specification must enable a skilled person to make and use the full scope of the claimed invention without undue experimentation. In Amgen v. Sanofi (2023), the Supreme Court confirmed that functional genus claims in biotechnology must be enabled across their full scope, which makes broad claims defined only by function particularly vulnerable. For peptides, that means giving a clear route to making the claimed variants and demonstrating, with data, that they share the stated activity.
Utility and data
Provide credible evidence of the claimed therapeutic or biological effect, such as binding assays, cell-based assays, pharmacokinetics, stability data and in vivo results. For European filings, EPO case law requires that the claimed technical effect be at least plausible from the application as filed and later-filed data cannot generally be used alone to establish it.
Best mode and definiteness
Applicants must disclose the best mode known at filing, though it is no longer a basis for invalidity after the America Invents Act. Claims must be definite: define terms such as “conservative substitution,” “variant” and “percent identity,” including how identity is calculated and over which length.
5. Drafting the Specification
A strong peptide specification typically includes the following components:
- Background and problem addressed, such as poor stability, short half-life or low selectivity of existing peptides.
- Summary of the peptide and its key sequence features, including motifs, essential residues and positions open to variation.
- Definitions of terms, abbreviations, amino acid codes, modifications and identity calculations.
- Detailed description of sequences and variants, listing exemplary sequences with SEQ ID NOs and describing permitted substitutions, truncations, extensions and modifications.
- Chemical structure drawings for non-standard peptides, cyclic structures, linkers and conjugates, which cannot be fully captured by a linear sequence.
- Methods of synthesis, such as solid-phase peptide synthesis, recombinant expression where relevant, purification and analytical characterization.
- Pharmaceutical compositions, routes of administration, dosage ranges, regimens and formulations, including salts and counterions.
- Examples and data, including controls and comparisons with prior art peptides.
- Methods of use, specifying diseases or conditions, patient populations and combination therapies.
6. Claim Strategy
A layered claim set gives flexibility during prosecution and litigation. Typical categories are listed below.
| Claim type | Example focus | Strengths and risks |
| Specific sequence | A peptide consisting of SEQ ID NO: 1 | Clear and defensible, but easy to design around. |
| Sequence identity or variant | A peptide at least 90% identical to SEQ ID NO: 1 and having activity X | Broader; needs strong written-description and enablement support. |
| Modified peptide | SEQ ID NO: 1 with a lipid moiety attached at position 20 | Supports eligibility and often defines commercial products. |
| Fragment or truncation | A fragment of at least 8 contiguous residues of SEQ ID NO: 1 | Check for anticipation by prior art sequences. |
| Composition | A pharmaceutical composition comprising the peptide and a specified excipient | Useful for lifecycle protection. |
| Method of treatment | A method of treating condition Y by administering the peptide at a defined dose | Strong against generics, but may depend on label use. |
| Process | A method of synthesizing the peptide comprising specified steps | Protects manufacturing know-how and can be hard to detect for infringement. |
- Choose “comprising” and “consisting of” deliberately. Open-ended language covers extended peptides, while closed language limits scope but can improve novelty over prior art.
- Use dependent claims to fall back to specific sequences, positions and modifications.
- Consider whether to claim features that matter commercially, such as half-life extension, oral bioavailability or reduced immunogenicity.
- Avoid reciting sequences that you do not need, because every recited sequence limits the claim.
7. Prior Art and Novelty
Peptide sequences can be anticipated or rendered obvious by a vast body of earlier literature. Search patent databases that support sequence searching (for example, those that index sequences from published patents and applications) alongside non-patent literature and public sequence databases such as GenBank, UniProt and PDB. Pay attention to:
- Naturally occurring peptides and known analogs, which may be disclosed as part of earlier genus claims.
- Prior art fragments that read on your claimed range of identity.
- Structure-activity relationships that make routine substitutions obvious. Evidence of unexpected results can be decisive in overcoming obviousness rejections.
- Your own earlier disclosures such as conference posters, preprints and investor presentations, which can bar later filings subject to the one-year grace period in the United States and the stricter rules elsewhere.
8. Filing Pathways and Timing
- Provisional application: A U.S. provisional gives a 12-month window to file a non-provisional and preserves a priority date, but it must be detailed enough to support later claims, including sequences and data.
- PCT application: Filing within 12 months of the first filing preserves international priority and defers national-phase costs, which generally begin at 30 months from priority (31 for the EPO).
- Sequence listing in PCT applications: An ST.26 listing should accompany the international application to avoid later requests to furnish one.
- Track One or other prioritized examination: Consider whether speed matters for investor, partnership or regulatory reasons.
- Continuations: Maintain continuation or divisional families to pursue different aspects, such as new variants or uses, as development progresses.
9. Lifecycle and Term Extension
Pharmaceutical patents can be extended to compensate for regulatory review time. In the United States, 35 U.S.C. § 156 allows patent term extension for patents covering an approved drug product and in Europe, Supplementary Protection Certificates play a similar role. For a peptide, a patent that claims the approved active ingredient, a method of use or a method of manufacture may qualify, subject to the rules. Plan portfolios so that at least one strong patent covers the active ingredient itself and complement it with formulation, dosing and use patents.
10. Filing Checklist
- Confirm the invention is eligible: modified or non-natural features, or claims to uses, formulations or processes.
- Prepare an ST.26-compliant XML sequence listing, validate it using WIPO Sequence and check that SEQ ID NOs match the text.
- Provide chemical structures for modified, cyclic or conjugated peptides.
- Include data supporting activity, stability and selectivity, along with comparisons to the closest prior art.
- Describe representative variants and a clear route to making them to support any genus claims.
- Define terms such as percent identity, conservative substitution and fragment.
- Draft a layered claim set covering sequence, modification, composition, use and process claims.
- Run prior-art searches including sequence-based searches and cite relevant references in an information disclosure statement.
- Check priority dates, public disclosures and the grace-period position before filing.
- Plan the filing route (provisional, PCT, national phase) and docket all deadlines.
Conclusion
Patenting peptides rewards careful preparation. The sequence listing is a formal requirement, but the larger challenges are substantive: demonstrating eligibility, supporting claim breadth with real data and representative variants and building a claim portfolio that covers the molecule, its modifications, its formulations and its uses. Applicants who plan the specification and sequence listing together and who align their filing strategy with regulatory and commercial goals, will be best placed to secure durable protection.
